New York, NY -- (SBWIRE) -- 02/01/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
StockMarketIntel.com issues a special report on the following stocks: Chelsea Therapeutics International Ltd. (NASDAQ:CHTP), Align Technology, Inc. (NASDAQ:ALGN), Hemispherx BioPharma, Inc (NYSEMKT:HEB), PerkinElmer, Inc. (NYSE:PKI)
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) declined -1.55%, trading on 2.43 million shares, to end the trade at $4.45. If we look at its trading history of the past 52 weeks, the share price suffered a low of $0.76 and was moved to the maximum level of $5.78. The stock changed hands in a range of $4.35 to $4.51, bringing its market capitalization to about $349.03 million. Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), associated with primary autonomic failure and falls related to NOH in Parkinson’s Disease (PD), as well as other norepinephrine-related conditions and diseases, including intradialytic hypotension (IDH), fibromyalgia, adult attention deficit hyperactivity disorder (ADHD), chronic fatigue syndrome (CFS), freezing of gait in PD and Down syndrome.
Will CHTP Bounce Back After yesterday’s Sharp Sell off? Find Out Here
Align Technology, Inc. (NASDAQ:ALGN) added 1.59%, to complete the trading session at $59.42, with a total volume of 2.42 million shares. The stock, on average, trades on a volume of 1.49 million shares. In the past 52 weeks, the share price has not declined below $29.53 and above $65.10. It floated in a range of $55.75 to $59.74 during the last trading session, with a beta value of 2.01. Its market capitalization now moved to about $4.74 billion. Align Technology, Inc (Align), designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design and computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics, and dental records storage.
For How Long ALGN will fight for Profitability? Read This Trend Analysis report
Hemispherx BioPharma, Inc (NYSEMKT:HEB) recorded a fall of -1.14% and was in a range of $0.41-$0.46 before closing at $0.435. The share price hit its 52-week low of $0.18 and $0.55 was the best price. The stock completed the day with a total volume of 2.48 million shares, versus an average volume of 4.68 million shares. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.
Is it the Right to Grab HEB after the Recent Slump? Get Free Trend Analysis Here
PerkinElmer, Inc. (NYSE:PKI) declined -1.00% yesterday, bringing its market capitalization around $4.90 billion. The total number of shares that changed hands during the session was 2.38 million shares, as compared to average trading volume of 805,821 shares. The share price, after opening at $45.84, made a high of $45.86 and hovered above $43.14 to end the day at $43.60. PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. Through the Company’s advanced technologies, solutions, and services, it addresses issues related to health and safety of people and their environment.
Will PKI Reach the Bottom after Yesterday’s Correction? Find Out Here
To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)